These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of the intrarenal renin-angiotensin system in experimental alport syndrome. Bae EH; Konvalinka A; Fang F; Zhou X; Williams V; Maksimowski N; Song X; Zhang SL; John R; Oudit GY; Pei Y; Scholey JW Am J Pathol; 2015 May; 185(5):1423-35. PubMed ID: 25777062 [TBL] [Abstract][Full Text] [Related]
3. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109 [TBL] [Abstract][Full Text] [Related]
4. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Zhong J; Guo D; Chen CB; Wang W; Schuster M; Loibner H; Penninger JM; Scholey JW; Kassiri Z; Oudit GY Hypertension; 2011 Feb; 57(2):314-22. PubMed ID: 21189404 [TBL] [Abstract][Full Text] [Related]
5. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ. Suh SH; Choi HS; Kim CS; Kim IJ; Ma SK; Scholey JW; Kim SW; Bae EH Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390839 [TBL] [Abstract][Full Text] [Related]
6. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218 [TBL] [Abstract][Full Text] [Related]
7. Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling. Jin HY; Chen LJ; Zhang ZZ; Xu YL; Song B; Xu R; Oudit GY; Gao PJ; Zhu DL; Zhong JC J Transl Med; 2015 Aug; 13():255. PubMed ID: 26245758 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-[1-7] attenuates kidney injury in experimental Alport syndrome. Choi HS; Kim IJ; Kim CS; Ma SK; Scholey JW; Kim SW; Bae EH Sci Rep; 2020 Mar; 10(1):4225. PubMed ID: 32144368 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. Wysocki J; Ye M; Khattab AM; Fogo A; Martin A; David NV; Kanwar Y; Osborn M; Batlle D Kidney Int; 2017 Jun; 91(6):1336-1346. PubMed ID: 27927599 [TBL] [Abstract][Full Text] [Related]
10. CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome. Suh SH; Choi HS; Kim CS; Kim IJ; Cha H; Cho JM; Ma SK; Kim SW; Bae EH Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098220 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547 [TBL] [Abstract][Full Text] [Related]
13. Deletion of Angiotensin-Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7 for Ubiquitin Degradation. Liu Z; Huang XR; Chen HY; Fung E; Liu J; Lan HY Hypertension; 2017 Oct; 70(4):822-830. PubMed ID: 28808068 [TBL] [Abstract][Full Text] [Related]
14. Albumin contributes to kidney disease progression in Alport syndrome. Jarad G; Knutsen RH; Mecham RP; Miner JH Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675 [TBL] [Abstract][Full Text] [Related]
15. Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment. Kim M; Piaia A; Shenoy N; Kagan D; Gapp B; Kueng B; Weber D; Dietrich W; Ksiazek I PLoS One; 2015; 10(11):e0141231. PubMed ID: 26555339 [TBL] [Abstract][Full Text] [Related]
16. Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome. Guo J; Song W; Boulanger J; Xu EY; Wang F; Zhang Y; He Q; Wang S; Yang L; Pryce C; Phillips L; MacKenna D; Leberer E; Ibraghimov-Beskrovnaya O; Ding J; Liu S Hum Gene Ther; 2019 Jul; 30(7):865-881. PubMed ID: 30808234 [TBL] [Abstract][Full Text] [Related]
17. Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction. Le Y; Zheng Z; Xue J; Cheng M; Guan M; Xue Y J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27913661 [TBL] [Abstract][Full Text] [Related]
18. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. Zhang ZZ; Shang QH; Jin HY; Song B; Oudit GY; Lu L; Zhou T; Xu YL; Gao PJ; Zhu DL; Penninger JM; Zhong JC J Transl Med; 2013 Sep; 11():229. PubMed ID: 24067190 [TBL] [Abstract][Full Text] [Related]
19. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Sahara M; Ikutomi M; Morita T; Minami Y; Nakajima T; Hirata Y; Nagai R; Sata M Cardiovasc Res; 2014 Feb; 101(2):236-46. PubMed ID: 24193738 [TBL] [Abstract][Full Text] [Related]
20. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome. Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]